DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

ELV·Elevance Health, Inc.

$.
-. (-.%)
After Hours
High
$422.07
Open
$420.08
Market Cap
90.39B
52W High
$427.64
Low
$415.49
P. Close
$416.46
P/E
17.24
52W Low
$273.71
Fwd P/E
14.19
DailyIQ Est.
$442.69
Technical Score (1D)
82
BUY
News Sentiment
61
BULLISH
Analysts now project Q2 earnings of $6.18 per share for Elevance Health, a decline that signals a tightening earnings outlook. The same forecast also shows falling revenue expectations, which could compress the company’s valuation over the next trading week. In parallel, the firm was recently removed from the Russell 1000 Value‑Defensive and Defensive indexes and added to the Russell 1000 Dynamic Index, reflecting a shift in its perceived risk profile. This index reclassification may reduce defensive demand for the stock, potentially increasing its volatility in the coming days. The combination of lower guidance and a more dynamic index placement suggests that the market is re‑pricing ELV as a higher‑risk, higher‑return play. Traders should watch the upcoming earnings release for any surprise in EPS or operating margin, as it will confirm whether the company can offset the revenue decline. A better‑than‑expected operating margin could mitigate the negative revenue outlook and restore some defensive appeal. Conversely, a margin squeeze would reinforce the dynamic index narrative and could trigger a sell‑off. Keep an eye on member growth numbers, as they are a key driver of future revenue and could signal a turnaround or further weakness.
Earnings Summary
Elevance Health, Inc. (ELV) is a leading U.S. health benefits provider that offers a broad array of health plans and services, including pharmacy, specialty insurance, and care management, through its HealthOS platform and brands such as Anthem Blue Cross and Blue Shield. Operating in the healthcare plans sector, the company serves individuals, employer groups, and government programs, positioning it as a defensive play in the broader healthcare landscape. In the most recent reporting cycle, ELV’s Q1 2026 earnings reflected a dramatic EPS increase to $12.58 from $3.33 in Q4 2025, while revenue rose modestly to $49.49 billion from $49.31 billion, indicating a slight revenue uptick but a sharp earnings acceleration. Compared with the prior two quarters (Q3 2025 and Q2 2025), EPS averaged $7.43 versus $7.96 in the latest two quarters, and revenue averaged $49.75 billion versus $49.40 billion, underscoring a modest revenue decline but a continued upward trajectory in earnings. Over the last four quarters, ELV has beaten earnings estimates in three out of four periods (Q1 2025, Q3 2025, Q4 2025, and the recent Q1 2026 surge), while revenue has consistently grown each quarter, though it fell short of the Q4 2025 estimate. Historically, the company has maintained a steady YoY revenue growth of roughly 10% per quarter and has shown a pattern of EPS beats despite occasional revenue misses, suggesting resilient profitability. Recent analyst commentary has highlighted a bullish price‑target lift to $440 from $360 following the Q1 2026 earnings beat, while some analysts caution that weaker member growth and mounting cost pressures could temper Q2 2026 guidance; the company’s capital allocation discipline and managed‑care expansion are cited as mitigating factors. Investors should watch for the Q2 2026 earnings release for any revisions to cost‑control initiatives, member churn metrics, and regulatory updates that could influence ELV’s margin profile, as well as how the broader healthcare sector reacts to the company’s guidance.

EPS

EstBeatMiss
$1.71$4.78$7.85$10.93$14.00Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.21 - -
Q1'26$6.29$12.58+99.9%
Q4'25$3.13$3.33+6.5%
Q3'25$4.94$6.03+22.0%
Q2'25$8.96$8.84-1.4%
Q1'25$11.48$11.97+4.3%

Revenue

EstBeatMiss
$47.6B$48.4B$49.1B$49.9B$50.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$49.2B - -
Q1'26$48.0B$49.5B+3.2%
Q4'25$50.3B$49.3B-2.0%
Q3'25 - $50.1B -
Q2'25 - $49.4B -
Q1'25 - $48.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ELV Stock Snapshot

ELV is currently trading at $416.23, giving Elevance Health, Inc. a market cap of 90.39B and a P/E ratio of 17.2. Today's range spans $415.49–$422.07, with shares opening at $420.08 and moving down $0.23 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 61/100.

Over the past year ELV has traded between $273.71 and $427.64 - the current price is +52.1% off the 52-week low and -2.7% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $431.48 (range $331.00–$498.00), implying upside of +3.7%.

Cross-asset context supports the bullish read on ELV: when Healthcare sector conditions are favorable, large-cap names with 82/100 technical scores (BUY) and bullish sentiment (61/100) outperform on a risk-adjusted basis. Price: $416.23 (near 52-week highs). (P/E: 17.2) The 52-week context of $273.71–$427.64 shows the full trading history - and the current setup is one of the stronger entries within that range. At 90.39B in market cap, position sizing is the key variable, not the direction.

What makes ELV's BUY setup (82/100) particularly actionable at 90.39B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $416.23 (near 52-week highs in $273.71–$427.64), with sentiment running bullish at 61/100, the setup rewards conviction-sized positioning more than it does speculative small bets.